The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program
Open accessAbstract
BACKGROUND: When combined with ceftazidime, the novel non-β-lactam β-lactamase inhibitor avibactam provides a carbapenem alternative against multidrug-resistant infections. Efficacy and safety of ceftazidime-avibactam plus metronidazole were compared with meropenem in 1066 men and women with complicated intra-abdominal infections from 2 identical, randomized, double-blind phase 3 studies (NCT01499290 and NCT01500239). METHODS: The primary end point was clinical cure at test-of-cure visit 28-35 days after randomization, assessed by noninferiority of ceftazidime-avibactam plus metronidazole to meropenem in the microbiologically modified intention-to-treat (mMITT) population (in accordance with US Food and Drug Administration guidance), and the modified intention-to-treat and clinically evaluable populations (European Medicines Agency guidance). Noninferiority was considered met if the lower limit of the 95% confidence interval for between-group difference was greater than the prespecified noninferiority margin of -12.5%. RESULTS: Ceftazidime-avibactam plus metronidazole was noninferior to meropenem across all primary analysis populations. Clinical cure rates with ceftazidime-avibactam plus metronidazole and meropenem, respectively, were as follows: mMITT population, 81.6% and 85.1% (between-group difference, -3.5%; 95% confidence interval -8.64 to 1.58); modified intention-to-treat, 82.5% and 84.9% (-2.4%; -6.90 to 2.10); and clinically evaluable, 91.7% and 92.5% (-0.8%; -4.61 to 2.89). The clinical cure rate with ceftazidime-avibactam plus metronidazole for ceftazidime-resistant infections was comparable to that with meropenem (mMITT population, 83.0% and 85.9%, respectively) and similar to the regimen's own efficacy against ceftazidime-susceptible infections (82.0%). Adverse events were similar between groups. CONCLUSIONS: Ceftazidime-avibactam plus metronidazole was noninferior to meropenem in the treatment of complicated intra-abdominal infections. Efficacy was similar against infections caused by ceftazidime-susceptible and ceftazidime-resistant pathogens. The safety profile of ceftazidime-avibactam plus metronidazole was consistent with that previously observed with ceftazidime alone. CLINICAL TRIALS REGISTRATION: NCT01499290 and NCT01500239.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Interval estimation for the difference between independent proportions: comparison of eleven methods
Newcombe, R. G. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19980430)17:8<873::aid-sim779>3.0.co;2-i · Cited by 1,851
Three Decades of β-Lactamase Inhibitors
Drawz, S. M., & Bonomo, R. A. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00037-09 · Cited by 1,709
Comparative analysis of two rates
Miettinen, O., & Nurminen, M. (1985) · Statistics in Medicine · doi:10.1002/sim.4780040211 · Cited by 1,110
The emerging NDM carbapenemases
Nordmann, P., Poirel, L., Walsh, T. R., & Livermore, D. M. (2011) · Trends in Microbiology · doi:10.1016/j.tim.2011.09.005 · Cited by 663
Solomkin, J., Hershberger, E., Miller, B., Popejoy, M., Friedland, I., Steenbergen, J., Yoon, M., Collins, S., Yuan, G., Barie, P. S., et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ097 · Cited by 420
2013 WSES guidelines for management of intra-abdominal infections
Sartelli, M., Viale, P., Catena, F., Ansaloni, L., Moore, E., Malangoni, M., Moore, F. A., Velmahos, G., Coimbra, R., Ivatury, R., et al. (2013) · World Journal of Emergency Surgery · doi:10.1186/1749-7922-8-3 · Cited by 314
Complicated intra-abdominal infections worldwide: the definitive data of the CIAOW Study
Sartelli, M., Catena, F., Ansaloni, L., Coccolini, F., Corbella, D., Moore, E. E., Malangoni, M., Velmahos, G., Coimbra, R., Koike, K., et al. (2014) · World Journal of Emergency Surgery · doi:10.1186/1749-7922-9-37 · Cited by 313
Kanj, S. S., & Kanafani, Z. A. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0674 · Cited by 269
Lucasti, C., Popescu, I., Ramesh, M. K., Lipka, J., & Sable, C. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks523 · Cited by 234
Vazquez, J. A., González Patzán, L. D., Stricklin, D., Duttaroy, D. D., Kreidly, Z., Lipka, J., & Sable, C. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.748653 · Cited by 219
Carbapenem-resistant Enterobacteriaceae: A menace to our most vulnerable patients
Perez, F., & Van Duin, D. (2013) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.80a.12182 · Cited by 184
Aktaş, Z., Kayacan, C., & Oncul, O. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.09.012 · Cited by 169
Stachyra, T., Péchereau, M.-C., Bruneau, J., Claudon, M., Frère, J., Miossec, C., Coleman, K., & Black, M. T. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00568-10 · Cited by 145
Livermore, D. M., Mushtaq, S., Warner, M., Miossec, C., & Woodford, N. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn320 · Cited by 120
Crandon, J. L., Schuck, V., Banevicius, M. A., Beaudoin, M., Nichols, W. W., Tanudra, M. A., & Nicolau, D. P. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00851-12 · Cited by 118
LUCASTI, C. J., Hershberger, E., Miller, B. W., Yankelev, S., Steenbergen, J. N., Friedland, I. R., & Solomkin, J. S. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00049-14 · Cited by 114
Mohr, J. (2008) · Clinical Infectious Diseases · doi:10.1086/590065 · Cited by 71
Current strategies for the treatment of complicated intraabdominal infections
Skrupky, L. P., Pennington, B. R. T., & Mazuski, J. E. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.821109 · Cited by 21
Self-citation
Cited by
Tamma, P. D., Heil, E. L., Justo, J. A., Mathers, A. J., Satlin, M. J., & Bonomo, R. A. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae403 · Cited by 1,191
Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad428 · Cited by 740
Rodríguez-Baño, J., Gutiérrez-Gutiérrez, B., Machuca, I., & Pascual, A. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00079-17 · Cited by 704
Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections
Doi, Y. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz830 · Cited by 652
The Surgical Infection Society Revised Guidelines on the Management of Intra-Abdominal Infection
Mazuski, J. E., Tessier, J. M., May, A. K., Sawyer, R. G., Nadler, E. P., Rosengart, M. R., Chang, P. K., O'Neill, P. J., Mollen, K. P., Huston, J. M., et al. (2017) · Surgical Infections · doi:10.1089/sur.2016.261 · Cited by 573
Self-citation
Metadata
- Authors
- Mazuski, J. E., Gasink, L. B., Armstrong, J., Broadhurst, H., Stone, G. G., Rank, D., Llorens, L., Newell, P., & Pachl, J.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-03-08
- Volume
- 62
- Issue
- 11
- Pages
- 1380-1389
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2294833633
- Cited by
- 393
- References
- 19
- FWCI
- 20.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.